Page 1

■ VISTIN PHARMA ASA - THIRD QUARTER REPORT 2021 VISTIN PHARMA VISTIN PHARMA ASA THIRD QUARTER AND YTD 2021 RESULTS PUBLISHED 28 OCTOBER 2021 HIGHLIGHTS 14 % increase in revenue for the quarter compared to Q3-20 . Revenue of MNOK 63 compared to MNOK 55 in third quarter 2020. Revenue increase driven by higher sales volume ( + 12 % ) and sales prices , offset by a significant stronger NOK vs EUR Revenue of MNOK 201 YTD in 2021 compared to MNOK 189 YTD in 2020 , a growth of 6 % 1 EBITDA of MNOK 4.6 in third quarter 2021 compared to MNOK 9.5 in third quarter 2020 ( -52 % ) . EBITDA unfavorably affected by FX , increased raw material prices , record high international freight costs ( + 600 % ) due to global constraints following Covid - 19 and significantly higher electricity prices in the quarter compared to last year YTD 2021 EBITDA of MNOK 36.5 versus MNOK 44.3 YTD in 2020 On track for a record high production volume in 2021 Long and uncertain freight lead times from Asia to Europe Metformin capacity expansion project ( MEP ) on track and expected to be commercially operational from Q2 2022. Approximately 55 % of the total investment of MNOK 100 paid as of end September Cash balance of MNOK 52 as of 30 September and no interest - bearing debt